Your web browser does not support JavaScript, but it does not affect browsing through the rest of the web site.

Novel Collagen Scaffold–Based Biologics (Collabody)

Font size:
Small
Medium
Large

Novel Collagen Scaffold–Based Biologics (Collabody)

The patented novel Anti–EGFR Collabody–drug conjugate (CDC) outrivals traditional technologies with many advantages:
1. The triploid Anti–EGFR CDC has the ability to produce sufficient cross–linking against EGFR of cancer cells, thereby achieving endocytosis more easily. It can rapidly merge with lysosome to quickly release highly toxic drugs and kill cancer cells.
2. Anti–EGFR CDC can be combined with highly toxic drugs at target sites to simplify the production process and reduce production costs.
3. Anti–EGFR CDC has a shorter half–life than antibody–drug conjugates (ADC). It is less toxic and more suitable for general tumor targets (such as EGFR), and can reduce harmful side effects on normal tissue.

Anti–EGFR Collabody Drug Conjugate.
Anti–EGFR Collabody Drug Conjugate.